Core Insights - IQVIA Holdings Analytics Inc. reported strong fourth-quarter 2024 results, with earnings and revenues exceeding the Zacks Consensus Estimate [1][2] Financial Performance - Adjusted earnings were $3.12 per share, a 9.9% increase year-over-year, slightly above the consensus estimate [2] - Total revenues reached $4 billion, surpassing the consensus estimate and growing 2.3% from the previous year [2] - Adjusted EBITDA for the quarter was $996 million, a 3.1% rise from the year-ago quarter, but below the projection of $1 billion [5] Segment Performance - Research and Development segment revenues were $2.1 billion, a 1.3% increase year-over-year, but missed the estimate of $2.2 billion [3] - Technology and Analytics segment revenues grew 8.3% year-over-year to $1.7 billion, beating the estimate of $1.6 billion [4] - Contract Sales & Medical Solutions revenues decreased 4.8% year-over-year to $177 million, missing the projection of $187 million [4] Cash Flow and Debt - Net cash generated from operating activities was $885 million, with capital expenditure at $164 million, resulting in free cash flow of $721 million [6] - Cash and cash equivalents at the end of the quarter were $1.7 billion, up from $1.6 billion in the previous quarter, while long-term debt increased to $12.8 billion from $12.3 billion [5] 2025 Guidance - Revenue guidance for 2025 was raised to $15.72-$16.12 billion, although the midpoint is lower than the Zacks Consensus Estimate of $16.02 billion [7] - Adjusted EPS guidance was increased to $11.70-$12.10, with the midpoint exceeding the Zacks Consensus Estimate of $11.8 per share [8] - Adjusted EBITDA guidance for 2025 was raised to $3.76-$3.88 billion, compared to the previous estimate of $3.67-$3.70 billion [8]

Q4 2024 Earnings Call February 6, 2025 IQVIA Template (V2.1.0) 1 Legal This presentation should be viewed in conjunction with IQVIA's Q4 2024 earnings call Safe Harbor Statement for Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, our first-quarter and full-year ...

Financial Data and Key Metrics Changes - For Q4 2024, revenue was $3,958 million, growing 2.3% on a reported basis and 3% at constant currency, with COVID-related revenues approximately $10 million, down about $50 million from Q4 2023 [40] - Full year revenue was $15,405 million, up 2.8% reported and 3.4% at constant currency, with COVID-related revenue totaling approximately $110 million for the year [42] - Adjusted diluted earnings per share for Q4 was $3.12, increasing 9.9% year-over-year, while full year adjusted diluted EPS was $11.13 [47] Business Line Data and Key Metrics Changes - Technology & Analytics Solutions (TAS) revenue for Q4 was $1,658 million, up 8.3% reported and 9.5% at constant currency [41] - R&D Solutions (R&DS) revenue for Q4 was $2,123 million, down 1.3% reported and 1% at constant currency, but grew over 1% at constant currency excluding COVID-related work [41] - Contract Sales & Medical Solutions (CSMS) revenue for Q4 was $177 million, declining 4.8% reported and 3.2% at constant currency [41] Market Data and Key Metrics Changes - Full year biotech funding exceeded $100 billion, a 44% increase from 2023, indicating a strong funding environment for the biotech sector [24] - R&DS backlog at December 31 was $31.1 billion, an increase of 4.4% year-over-year and 5.5% at constant currency [48] Company Strategy and Development Direction - The company aims to sustain favorable trends into 2025, with a focus on innovation and AI-enabled applications, having introduced 60 innovations including 39 AI-enabled applications in 2024 [19][59] - The company has partnerships with 22 of the top 25 pharma companies and has successfully renewed all large pharma strategic partnerships [14][15] Management's Comments on Operating Environment and Future Outlook - Management noted a challenging macro environment in 2024, including geopolitical unrest and high interest rates, but highlighted that IQVIA outperformed many competitors in the industry [11][12] - The company expects some volatility in R&DS demand for the next couple of quarters but believes the bulk of portfolio reprioritizations at large pharma has been completed [22][66] Other Important Information - The company achieved record free cash flow of $721 million in Q4, bringing the full year total to over $2.1 billion, up 41% year-over-year [49][58] - The Board of Directors replenished the share repurchase authorization by $2 billion, increasing the total remaining authorization to approximately $3 billion [50][59] Q&A Session Summary Question: How did the operating environment progress through the quarter? - Management indicated that the operating environment remained difficult, with significant cancellations and delays in trials, but they believe most reprioritizations have occurred [62][66] Question: Can you provide more color on the biotech environment and RFP flow? - Biotech funding was strong, exceeding $100 billion in 2024, which is a leading indicator for future bookings, and RFP flow was up mid-single digits [74][75] Question: What were the cancellations in Q4? - Cancellations were elevated, approximately 50% higher than the average of the previous three years, but the company managed to grow its backlog despite this [81][83] Question: What are the cost levers being pulled to maintain margins? - The company is focusing on optimizing labor rates, restructuring, and leveraging AI tools to mitigate cost pressures while maintaining margin growth [90][99] Question: What is the outlook for the TAS segment? - The TAS segment is expected to remain resilient with consistent growth, particularly in real-world evidence and technology platforms, which have shown strong recovery [105][110]

Core Insights - IQVIA Holdings Inc reported a fourth adjusted EPS of $3.12, an increase from $2.84, surpassing the consensus of $3.11 [1] - The company achieved sales of $3.96 billion, nearly matching the consensus of $3.94 billion, with a revenue increase of 2.3% on a reported basis and 3.0% at constant currency [1] - The Technology & Analytics Solutions (TAS) segment generated revenue of $1.66 billion, reflecting an 8.3% growth on a reported basis and 9.5% at constant currency [1] Revenue Breakdown - Research & Development Solutions (R&DS) revenue was $2.123 billion, showing a decrease of 1.3% on a reported basis and 1.0% at constant currency [2] - The R&DS contracted backlog, including reimbursed expenses, reached $31.1 billion, growing 4.4% year-over-year and 5.5% at constant currency [2] - Approximately $7.9 billion of the backlog is expected to convert to revenue in the next twelve months, with a fourth-quarter book-to-bill ratio of 1.20x [2] Management Commentary - The CEO of IQVIA stated that the company delivered excellent fourth-quarter performance and that R&DS revenue was on target, with bookings exceeding expectations despite a challenging CRO market [2] - The TAS segment showed strong momentum, suggesting that the company's growth target for 2025 may be conservative [4] Guidance and Outlook - IQVIA reaffirms its 2025 sales outlook of $15.725 billion to $16.125 billion, compared to a consensus of $16.03 billion [2] - The company anticipates adjusted EPS of $11.70-$12.10, against a consensus of $11.88, and adjusted EBITDA of $3.765 billion to $3.885 billion [3] - Stronger-than-expected bookings in the R&DS segment enhance confidence in achieving mid-single-digit revenue growth for 2025, excluding COVID-related revenue [3] Market Reaction - Following the earnings report, IQV stock increased by 2.8%, reaching $211.36 [4]

IQVIA Holdings (IQV) reported $3.96 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 2.3%. EPS of $3.12 for the same period compares to $2.84 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $3.92 billion, representing a surprise of +0.89%. The company delivered an EPS surprise of +0.65%, with the consensus EPS estimate being $3.10.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- an ...

Core Insights - IQVIA Holdings reported quarterly earnings of $3.12 per share, exceeding the Zacks Consensus Estimate of $3.10 per share, and up from $2.84 per share a year ago, indicating a 9.86% year-over-year increase [1] - The company achieved revenues of $3.96 billion for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 0.89% and showing a year-over-year increase from $3.87 billion [2] - IQVIA has consistently outperformed consensus EPS and revenue estimates over the last four quarters, indicating strong operational performance [2] Earnings Outlook - The sustainability of IQVIA's stock price movement will largely depend on management's commentary during the earnings call and future earnings expectations [3][4] - Current consensus EPS estimate for the upcoming quarter is $2.59 on revenues of $3.85 billion, while for the current fiscal year, the estimate is $11.80 on revenues of $16.02 billion [7] Industry Context - The Medical - Instruments industry, to which IQVIA belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Exhibit 99.1 IQVIA Reports Fourth-Quarter and Full-Year 2024 Results; Reaffirms Full-Year 2025 Guidance RESEARCH TRIANGLE PARK, N.C. February 6, 2025 – IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today reported financial results for the quarter ended December 31, 2024. "IQVIA delivered excellent fourth quarter performance, closing out a strong 2024," said Ari ...

IQVIA Holdings Inc. (IQV) will release its fourth-quarter 2024 results on Feb. 6, before market open.See Zacks Earnings Calendar to stay ahead of market-making news.IQV has an impressive earnings surprise history, having surpassed the Zacks Consensus Estimate in the trailing four quarters, the average surprise being 1.7%.IQVIA Holdings Inc. Price, Consensus and EPS Surprise IQVIA’s Q4 ExpectationsThe Zacks Consensus Estimate for revenues is pegged at $3.9 billion, implying 1.4% growth from the year-ago quar ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium includes access to the Zacks Style Scores as we ...

The upcoming report from IQVIA Holdings (IQV) is expected to reveal quarterly earnings of $3.11 per share, indicating an increase of 9.5% compared to the year-ago period. Analysts forecast revenues of $3.92 billion, representing an increase of 1.4% year over year.The consensus EPS estimate for the quarter has been revised 0.4% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Prior t ...